^
Association details:
| Biomarker: | CDKN2A mutation |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Genomic profiling and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: An exploratory analysis from the phase 3 IMpassion130 tria
Published date:
11/17/2020
Excerpt:
...CNA in CDKN2A (12%) and CDKN2B (11%) were associated with improved PFS and OS clinical activity in the A + nP arm vs the P + nP arm (HR PFS, 0.43-0.44 and HR OS, 0.47, respectively).
Secondary therapy:
albumin-bound paclitaxel
Trial ID:
Test:
